Vol 52, No 3 (2021)
Original research article
Published online: 2021-06-28

open access

Page views 539
Article views/downloads 395
Get Citation

Connect on Social Media

Connect on Social Media

High mean platelet volume and neutrophil-to-lymphocyte ratio are predictors of mortality in patients with HIV-related non-Hodgkin’s lymphoma

Juan Camilo Salgado Sánchez1, Jorge Leonardo Gamboa Quiñones1, Oscar Mauricio Muñoz-Velandia12, Mónica Arévalo Zambrano23, José Roberto José Roberto Támara Ramírez124
Acta Haematol Pol 2021;52(3):195-201.


Introduction: Simple indices derived from a blood count are useful as predictors of survival in both solid and hematological tumors. However, these indices have not been studied in human immunodeficiency virus (HIV)-associated non-Hodgkin’s lymphoma (NHL). The present study evaluates whether there are differences in the survival of such patients at two years according to baseline values of mean platelet volume (MPV) and neutrophil-to-lymphocyte ratio (NLR). Material and methods: A retrospective cohort of patients between 2003 and 2018 with HIV and a confirmed diagnosis of some variant of nNHL at the Hospital Universitario San Ignacio, Bogotá, Colombia, was evaluated. 2-year survival was analyzed by comparing groups according to baseline values of MPV and NLR using Kaplan-Meier curves and log rank test. Cox regression model was used to control for confounding factors. Results: 31 patients were included. The combined follow-up time was 602 months. Ten patients died during follow-up. The 2-year survival was lower for patients with MPV > 7.5 fL (41.6 vs. 84.0%, p =0.01, log rank test: 0.0057) and NLR > 4.35 (33.0% vs. 76.0%, p =0.04; log rank test 0.028). Mortality was higher in patients with MPV > 7.5 fL (HR 6.39; confidence interval 95% 1.35–30.21, p =0.015) controlling by the effect of type of lymphoma, International Prognostic Index and functionality. Conclusion: High values of MPV and NLR at the time of diagnosis of NHL are associated with mortality in patients with HIV infection. It is necessary to evaluate the utility of including these markers in prognostic indices.

Article available in PDF format

View PDF Download PDF file


  1. Akanmu AS. AIDS-associated malignancies. Afr J Med Med Sci. 2006; 35(Suppl): 57–70.
  2. Vandenhende MA, Roussillon C, Henard S, et al. ANRS EN20 Mortalité 2010 study group. Cancer-related causes of death among HIV-Infected patients in France in 2010: evolution since 2000. PLoS One. 2015; 10(6): e0129550.
  3. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol. 2006; 60(12): 1365–1372.
  4. Schommers P, Gillor D, Hentrich M, et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018; 103(5): 857–864.
  5. Cuellar LE, Anampa-Guzmán A, Holguín AM, et al. Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience. Infect Agent Cancer. 2018; 13: 27.
  6. Han X, Jemal A, Hulland E, et al. HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy. Cancer Epidemiol Biomark Prev. 2016.
  7. Marcucci F, Spada E, Mele A, et al. The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma – a review. Am J Blood Res. 2012; 2(1): 18–28.
  8. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005; 55(6): 368–376.
  9. Huang HH, Xiao F, Chen FY, et al. Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study. Exp Ther Med. 2012; 4(3): 475–480.
  10. Wang Y, Qiu H, Hu W, et al. Over-expression of platelet-derived growth factor-D promotes tumor growth and invasion in endometrial cancer. Int J Mol Sci. 2014; 15(3): 4780–4794.
  11. Baldane S, Ipekci SH, Sozen M, et al. Mean platelet volume could be a possible biomarker for papillary thyroid carcinomas. Asian Pac J Cancer Prev. 2015; 16(7): 2671–2674.
  12. Tanriverdi O, Menekse S, Teker F, et al. The mean platelet volume may predict the development of isolated bone metastases in patients with breast cancer: A retrospective study of the Young Researchers Committee of the Turkish Oncology Group (TOG). J BUON. 2016; 21(4): 840–850.
  13. Tuncel T, Ozgun A, Emirzeoglu L, et al. Mean platelet volume as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab-combined chemotherapy. Asian Pac J Cancer Prev. 2014; 15(15): 6421–6423.
  14. Xue P, Kanai M, Mori Y, et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med. 2014; 3(2): 406–415.
  15. Raffetti E, Donato F, Casari S, et al. Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort study. BMC Infect Dis. 2017; 17(1): 193.
  16. Hanberg JS, Freiberg MS, Goetz MB, et al. VACS Project Team. . Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic inflammatory biomarkers in human immunodeficiency virus (HIV), hepatitis C virus (HCV), and HIV/HCV coinfection. Open Forum Infect Dis. 2019; 6(10): ofz347.
  17. Mu S, Ai L, Fan F, et al. Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis. Cancer Cell Int. 2018; 18: 119.
  18. Nkambule BB, Davison GM, Ipp H. The evaluation of platelet indices and markers of inflammation, coagulation and disease progression in treatment-naïve, asymptomatic HIV-infected individuals. Int J Lab Hematol. 2015; 37(4): 450–458.
  19. Qadri S, Holman S, Dehovitz J, et al. Mean platelet volume is decreased in HIV-infected women. HIV Med. 2013; 14(9): 549–555.
  20. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory testing for the diagnosis of HIV infection: updated recommendations. http://stacks.cdc.gov/view/cdc/23447 (January 1, 2020).
  21. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375–2390.
  22. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6): dju124.
  23. Korniluk A, Koper-Lenkiewicz OM, Kamińska J, et al. Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediators Inflamm. 2019; 2019: 9213074.
  24. Younes A, Hilden P, Coiffier B, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017; 28(7): 1436–1447.
  25. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649–655.
  26. Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression. Third edition. John Wiley & Sons, Inc., [City??] 2013.
  27. Djordjevic D, Rondovic G, Surbatovic M, et al. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume-to-platelet count ratio as biomarkers in critically ill and injured patients: which ratio to choose to predict outcome and nature of bacteremia? Mediators Inflamm. 2018; 2018: 3758068.
  28. Heeke S, Mograbi B, Alix-Panabières C, et al. Never travel alone: the crosstalk of circulating tumor cells and the blood microenvironment. Cells. 2019; 8(7).
  29. Palacios-Acedo AL, Mège D, Crescence L, et al. Platelets, thrombo-inflammation, and cancer: collaborating with the enemy. Front Immunol. 2019; 10: 1805.
  30. Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018; 131(16): 1777–1789.
  31. Apollonio B, Ramsay AG. Exosomes and CAFs: partners in crime. Blood. 2015; 126(9): 1053–1055.
  32. Qiu GZ, Jin MZ, Dai JX, et al. Reprogramming of the tumor in the hypoxic niche: the emerging concept and associated therapeutic strategies. Trends Pharmacol Sci. 2017; 38(8): 669–686.
  33. Rupa-Matysek J, Gil L, Barańska M, et al. Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma. Oncotarget. 2018; 9(30): 21190–21200.
  34. Rupa-Matysek J, Gil L, Kroll-Balcerzak R, et al. Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B-cell lymphoma. Hematol Oncol. 2017; 35(4): 456–464.